Foghorn Therapeutics Inc. (FHTX)
NASDAQ: FHTX · Real-Time Price · USD
4.520
-0.150 (-3.21%)
Sep 10, 2026, 10:18 AM EDT - Market open
Foghorn Therapeutics Stock Forecast
Stock Price Forecast
According to 10 analysts polled by S&P Global, Foghorn Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $11.44. The average 1-year stock price forecast is 153.10% higher than the current stock price, while the lowest is $9.00 (+99.12%) and the highest is $14 (+209.73%).
Price Target: $11.44 (+153.10%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Foghorn Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 9 | 9 | 9 | 9 | 9 | 9 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 10 | 10 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
Unknown Analyst B. Riley Securities No rating | B. Riley Securities | Buy Initiates $10 | Buy | Initiates | $10 | +121.24% | Aug 27, 2026 |
| Stifel Nicolaus | Stifel Nicolaus | Buy Maintains $12 | Buy | Maintains | $12 | +165.49% | Aug 17, 2026 |
Unknown Analyst Evercore ISI No rating | Evercore ISI | Buy Maintains $14 | Buy | Maintains | $14 | +209.73% | Aug 10, 2026 |
| BTIG | BTIG | Buy Maintains $11 | Buy | Maintains | $11 | +143.36% | Aug 7, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $13 | Buy | Reiterates | $13 | +187.61% | Aug 7, 2026 |
Financial Forecast
Revenue This Year
33.92M
from 30.91M
Increased by 9.74%
Revenue Next Year
32.77M
from 33.92M
Decreased by -3.39%
EPS This Year
-0.88
from -1.21
EPS Next Year
-1.09
from -0.88
EPS and Forward PE are based on non-GAAP adjusted numbers.